SCHEMBL3540299

SCHEMBL3540299

CCc1c[nH]c(=S)[nH]c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
KDM3B Q7LBC6 1/20 0.47
FFAR3 O14843 3/20 0.42
HCAR2 Q8TDS4 3/20 0.42
GRIN2D O15399 2/20 0.40
GRIN3B O60391 2/20 0.40
GRIN1 Q05586 2/20 0.40
GRIN2A Q12879 2/20 0.40
GRIN2B Q13224 2/20 0.40
GRIN2C Q14957 2/20 0.40
GRIN3A Q8TCU5 2/20 0.40
UBE2N P61088 1/20 0.38
MEN1 O00255 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TP53 P04637 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
FFAR2 O15552 1/20 0.34
SLC22A4 Q9H015 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691795 0.86 KMT2A (0.55) KMT2ATDP1KDM3BFFAR3HCAR2
SCHEMBL10983716 0.83 KMT2A (0.53) KMT2ATDP1KDM3BFFAR3HCAR2
SCHEMBL11343851 0.81 KMT2A (0.51) KMT2ATDP1KDM3BFFAR3HCAR2
SCHEMBL21345745 0.81 KMT2A (0.54) KMT2ATDP1KDM3BUBE2NMEN1
SCHEMBL18640304 0.81 KMT2A (0.50) KMT2ATDP1KDM3BFFAR3HCAR2
SCHEMBL153562 0.80 KMT2A (0.50) KMT2ATDP1KDM3BUBE2NKDM4E
SCHEMBL29007135 0.80 KMT2A (0.54) KMT2ATDP1KDM3BUBE2NMEN1
SCHEMBL10735494 0.80 KMT2A (0.50) KMT2ATDP1KDM3BFFAR3HCAR2
SCHEMBL3537530 0.78 KMT2A (0.51) KMT2ATDP1KDM3BUBE2NMEN1
SCHEMBL8508881 0.77 KMT2A (0.48) KMT2ATDP1KDM3BFFAR3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9875904-B2 Silicon etching liquid, silicon etching method, and microelectromechanical element MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2018-01-23 US claimed
US-20150340241-A1 SILICON ETCHING LIQUID, SILICON ETCHING METHOD, AND MICROELECTROMECHANICAL ELEMENT MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-11-26 US claimed
US-8841062-B2 Positive working photosensitive material AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) 2014-09-23 US claimed
US-20140154624-A1 POSITIVE WORKING PHOTOSENSITIVE MATERIAL AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (US) 2014-06-05 US claimed
US-4002479-A ORGANIC SILVER SALT, SILVER HALIDE, AND A REDUCING AGENT FUJI PHOTO FILM CO., LTD. (JA) 1977-01-11 US claimed
US-12619149-B2 DNQ-free chemically amplified resist composition MERCK PATENT GMBH (DE) 2026-05-05 US disclosed
US-12393115-B2 Positive working photosensitive material MERCK PATENT GMBH (DE) 2025-08-19 US disclosed
US-20250244669-A1 COMPOSITIONS AND METHODS OF IMPROVING METAL STRUCTURE FABRICATION BY WET CHEMICAL ETCH EMD PERFORMANCE MATERIALS CORP. 2025-07-31 US disclosed
US-12360453-B2 PAG-free positive chemically amplified resist composition and methods of using the same MERCK PATENT GMBH (DE) 2025-07-15 US disclosed
CN-114651212-B Positive photosensitive material 默克专利股份有限公司 2025-05-02 CN disclosed
EP-4433873-A2 COMPOSITIONS AND METHODS FOR IMPROVING METAL STRUCTURE FABRICATION BY WET CHEMICAL ETCH Merck Patent GmbH (DE) 2024-09-25 EP disclosed
CN-112654928-B Positive photosensitive material 默克专利股份有限公司 2024-09-24 CN disclosed
EP-0449726-B1 Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient MITSUBISHI CHEM CORP (JP) 1997-06-11 EP disclosed
EP-0748316-A1 PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES SUNKYONG INDUSTRIES CO., LTD. (KR) 1996-12-18 EP disclosed
US-5461060-A Antiretroviral activity MITSUBISHI KASEI CORPORATION (JP) 1995-10-24 US disclosed
WO-1995023138-A1 PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES SUNKYONG INDUSTRIES CO., LTD. (KR) 1995-08-31 WO disclosed
US-5318972-A Active against retroviruses, human t-cell leukemia/lymphoma viruses MITSUBISHI KASEI CORPORATION (JP) 1994-06-07 US disclosed
EP-0449726-A1 Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient Mitsubishi Chemical Corporation (JP) 1991-10-02 EP disclosed
EP-0420763-A2 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof Mitsubishi Chemical Corporation (JP) 1991-04-03 EP disclosed
US-4002479-A ORGANIC SILVER SALT, SILVER HALIDE, AND A REDUCING AGENT FUJI PHOTO FILM CO., LTD. (JA) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12619149-B2 DNQ-free chemically amplified resist composition POLQ, RECQL, RPA1 KMT2A 2038/4885TDP1 413/4885KDM3B 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.